Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | March 23, 2026 | March 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date March 23, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 50,493 |
Reported balance
After 2026-03-23 transaction · row 1
1 source rowRow 1 · 2026-03-23 · Grant · Acquired 13,255 · Balance 50,493 F1: These shares represent a restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 2-year term, with 1/2 of the award vesting in any one year, beginning on March 23, 2027. The award includes the right to have shares withheld for tax purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent a restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 2-year term, with 1/2 of the award vesting in any one year, beginning on March 23, 2027. The award includes the right to have shares withheld for tax purposes.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EXACT SCIENCES CORP
Report date March 23, 2026 · Filed March 23, 2026
Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-03-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-23 · Grant · Acquired 53,323 · Balance 153,726 F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding. Row 2 · 2026-03-23 · Disposition to issuer · Disposed 153,726 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectHeld in 401(k) Plan | 0 |
Reported balance
After 2026-03-23 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-03-23 · Disposition to issuer · Disposed 1,774 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $98.18 | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-23 · Disposition to issuer · Disposed 6,581 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F4: These options became exercisable on February 14, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-23 · Disposition to issuer · Disposed 38,707 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F8: At the Effective Time, each RSU granted under an Issuer stock plan outstanding as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time. F7: These RSUs vest in four equal annual installments beginning on February 25, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.
F2: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding.
F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
F4: These options became exercisable on February 14, 2024.
F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
F7: These RSUs vest in four equal annual installments beginning on February 25, 2027.
F8: At the Effective Time, each RSU granted under an Issuer stock plan outstanding as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2020 Filed Feb 20, 2020 17:55 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 1,153 | $100.68 | $116,084.04 |
DisclosureSEC source: 0001209191-20-011235 · doc4.xml · nonDerivative · entry 2 ORVILLE JACOB A · CIK 0001263312 · General Manager, New Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,495 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 18, 2020. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 2,687 shares, Mr. Orville also holds, in the aggregate, an additional 25,649 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 17:55 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 3,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-011235 · doc4.xml · derivative · entry 4 ORVILLE JACOB A · CIK 0001263312 · General Manager, New Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,946 Underlying: Common Stock · 3,648 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 18, 2020. The restricted stock units vest in four equal annual installments beginning on February 18, 2020. F5 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 18, 2020. The restricted stock units vest in four equal annual installments beginning on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 17:55 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 3,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-011235 · doc4.xml · nonDerivative · entry 1 ORVILLE JACOB A · CIK 0001263312 · General Manager, New Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 16:39 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantStock Option (right to buy) · Derivative | 6,581 | $0.00 Strike: $98.18 | $0.00 |
DisclosureSEC source: 0001209191-20-010178 · doc4.xml · derivative · entry 3 ORVILLE JACOB A · CIK 0001263312 · General Manager, New Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,581 Underlying: Common Stock · 6,581 shares Expires 2030-02-14 F4 · derivative.exercise_date: These options vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 16:39 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantRestricted Stock Units · Derivative | 8,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010178 · doc4.xml · derivative · entry 2 ORVILLE JACOB A · CIK 0001263312 · General Manager, New Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,121 Underlying: Common Stock · 8,121 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: These restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: These restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.